Europe News
Filter News
Found 90,763 articles
-
GSK has discontinued a Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody aimed at treating ulcerative colitis licensed from Immutep Limited following an interim assessment of an Independent Data Monitoring Committee.
-
Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19
1/22/2021
Initial agreement provides up to 40 million doses to COVAX in 2021 First deliveries are expected to take place in Q1 2021 subject to the execution of supply agreements under the COVAX Facility structure
-
Nanoform's Clinical Study Indicates Positive Interim Results - Jan 22, 2021
1/22/2021
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, announced positive interim results from its clinical study.
-
Conference call Report on Operations 2020: Vitrolife
1/22/2021
Invitation to attend Vitrolife's conference call regarding presentation of the Report on Operations 2020.
-
Elekta divests its stake in ViewRay
1/22/2021
Elekta AB announced that it has sold its 7.3 percent of the outstanding common stock in ViewRay, Inc. Elekta has no remaining shares in ViewRay after the transaction..
-
David Fairley and Alan Williams accept invitation to join Offspring Biosciences Board of Directors
1/22/2021
Offspring Biosciences AB, a leading global provider of advanced molecular pathology services, announced that its Board of Directors has elected David Fairley and Alan Williams as Non-Executive Directors effective today.
-
Servier and MiNA Therapeutics are partnering on small activating RNA (saRNA) therapies to treat neurological diseases. saRNA is an entirely new class of drugs.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
-
The decision was made based on an Independent Data Monitoring Committee recommendation which indicated the study was unlikely to meet its specified primary efficacy endpoint of progression-free survival.
-
Medical-Fish-Skin Company Kerecis Names Mike Cadigan CFO
1/21/2021
Kerecis, the fastest growing company in the regenerative-tissue market in the United States, has appointed Mike Cadigan as its chief financial officer.
-
Merus Announces Pricing of Public Offering of Common Shares - Jan 21, 2021
1/21/2021
Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced the pricing of an underwritten public offering of 4,848,485 common shares at a public offering price of $24.75 per share.
-
NLS Pharmaceutics Ltd. Announces Notice of Allowance of a New Technology Patent Covering Attention Deficit Hyperactivity Disorder & Narcolepsy
1/21/2021
NLS Pharmaceutics Ltd., a Swiss biotech firm focusing on the development of novel treatments of rare neurological diseases including narcolepsy, idiopathic hypersomnia and Kleine-Levin Syndrome and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder, announced that the European Patent Office issued a Notice of Intention to Grant NLS's patent application covering a novel formulation of mazindol for treatment of ADHD and sleep related disorders.
-
Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases
1/21/2021
Amarin Corporation plc (NASDAQ:AMRN) today announced that the Chinese Society of Cardiology (CSC) has included icosapent ethyl in its updated Guidelines for Primary Prevention of Cardiovascular Diseases for 2021 as published in the Chinese Journal of Cardiovascular Diseases . The guideline authors include “icosapent ethyl 2 grams twice a day (as studied in REDUCE-IT ® ) as a treatment consideration to further lower ather
-
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment
1/21/2021
Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine to maintain viral suppression with 12 dosing days per year
-
Sartorius Stedim Biotech's $1.5 million donation creates cell culture facility at Penn State University
1/21/2021
Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has committed $1.5 million to Penn State University to create the Sartorius Cell Culture Facility. It is slated to open in the first quarter of 2021 on the University Park campus.
-
Antibiotic resistance may spread even more easily than expected
1/21/2021
Pathogenic bacteria in humans are developing resistance to antibiotics much faster than expected. Now, computational research at Chalmers University of Technology, Sweden, shows that one reason could be significant genetic transfer between bacteria in our ecosystems and to humans.
-
R-Pharm to study RPH-104 in acute ST-Elevation Myocardial Infarction
1/21/2021
R-Pharm announces first patients enrolled in international double blind placebo-controlled clinical trial of RPH-104 in acute ST-Elevation Myocardial Infarction (STEMI)
-
Menarini Receives European Commission Approval of ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
1/21/2021
The Menarini Group, a privately held Italian pharmaceutical and diagnostics company, announced today that the European Commission (EC) has granted a marketing authorization, for ELZONRIS (tagraxofusp) as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare
-
Bactiguard-coated Zimmer Biomet trauma implants receive European regulatory clearance
1/21/2021
Today, Bactiguard-coated Zimmer Biomet orthopaedic trauma implants received European regulatory clearance and CE mark. Preparations for registering the implants in the U.S. market are also ongoing.
-
XClinical to Merge with Carenity and Fortress Medical Systems Forming a New Data Science Company Serving Life Science Markets Worldwide
1/21/2021
XClinical, a leading vendor of eClinical software has announced a merger with France-based Carenity, a social platform supporting patients and caregivers worldwide, and Fortress Medical Systems, the US-based vendor of Clindex®, an integrated CTMS and EDC system